View ValuationAccelerate Diagnostics 将来の成長Future 基準チェック /06現在、 Accelerate Diagnosticsの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Medical Equipment 収益成長16.1%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報Major Estimate Revision • Apr 25Consensus EPS estimates fall by 15%The consensus outlook for fiscal year 2023 has been updated. 2023 expected loss increased from -US$0.46 to -US$0.53 per share. Revenue forecast of US$15.1m unchanged since last update. Medical Equipment industry in the US expected to see average net income growth of 16% next year. Consensus price target of US$0.60 unchanged from last update. Share price rose 32% to US$0.90 over the past week.Major Estimate Revision • Nov 21Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast fell from US$14.4m to US$12.7m. EPS estimate increased from -US$0.81 to -US$0.76 per share. Medical Equipment industry in the US expected to see average net income growth of 14% next year. Consensus price target down from US$4.00 to US$2.00. Share price fell 39% to US$0.92 over the past week.Price Target Changed • Nov 16Price target decreased to US$2.00Down from US$4.00, the current price target is provided by 1 analyst. New target price is 79% above last closing price of US$1.12. Stock is down 80% over the past year. The company is forecast to post a net loss per share of US$0.80 next year compared to a net loss per share of US$1.26 last year.Major Estimate Revision • Aug 22Consensus revenue estimates increase by 10%The consensus outlook for revenues in 2022 has improved. 2022 revenue forecast increased from US$12.9m to US$14.3m. Forecast losses expected to reduce from -US$1.04 to -US$0.77 per share. Medical Equipment industry in the US expected to see average net income growth of 9.7% next year. Consensus price target up from US$1.00 to US$4.00. Share price fell 47% to US$1.43 over the past week.Major Estimate Revision • May 23Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast fell from US$13.4m to US$12.9m. 2022 losses expected to reduce from -US$1.24 to -US$1.04 per share. Medical Equipment industry in the US expected to see average net income growth of 16% next year. Consensus price target down from US$5.00 to US$1.00. Share price fell 4.8% to US$0.58 over the past week.Price Target Changed • Apr 27Price target decreased to US$5.00Down from US$8.00, the current price target is an average from 4 analysts. New target price is 385% above last closing price of US$1.03. Stock is down 87% over the past year. The company is forecast to post a net loss per share of US$1.23 next year compared to a net loss per share of US$1.26 last year.すべての更新を表示Recent updatesお知らせ • Aug 19Accelerate Diagnostics, Inc. announced delayed 10-Q filingOn 08/18/2025, Accelerate Diagnostics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Jun 06+ 1 more updateFinal DIP Financing Approved for Accelerate Diagnostics, Inc.The US Bankruptcy Court gave an order to Accelerate Diagnostics, Inc. to obtain DIP financing on final basis on June 5, 2025. As per the order, the debtor has been authorized to obtain a new money term loan facility in the amount of $12.5 million from Indaba Capital Fund, LP and Streeterville Capital LLC with U.S. Bank Trust Company, National Association as DIP agent. As per the terms of the DIP agreement, the loan carries a structuring fee of $1 million, exit fee of $7.5 million and earned in stages 35% at interim order, 15% at dip credit agreement and 50% at final dip order, backstop fee of $1.5 million. The DIP facility would mature either on December 31, 2025, or earliest of loan acceleration or closing of an asset sale, whichever is earlier. Adequate protection would be provided to the DIP lenders in the form of super-priority administrative expense claims which is subject to a carve-out of $0.5 million towards unpaid professional fees / administrative expenses and first priority lien upon and security interest in the debtor’s collateral.お知らせ • May 17Accelerate Diagnostics, Inc. announced delayed 10-Q filingOn 05/16/2025, Accelerate Diagnostics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • May 16Accelerate Diagnostics, Inc.(OTCPK:AXDX.Q) dropped from NASDAQ Composite IndexAccelerate Diagnostics, Inc has been dropped from the NASDAQ Composite Indexお知らせ • May 13Accelerate Diagnostics Receives Delisting Determination and Minimum Bid Price Non-Compliance Letter from NasdaqAs previously disclosed, on May 8, 2025, Accelerate Diagnostics, Inc. (the “ Company”) and certain of its subsidiaries (together, the “ Debtors”) filed voluntary petitions (the “ Bankruptcy Petitions”) under Chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware (such court, the “ Court” and such cases, the “ Cases”). On May 8, 2025, the Company received written notice (the “ Delisting Notice”) from the Listing Qualifications Staff (the “ Staff”) of The Nasdaq Stock Market LLC (“ Nasdaq”) notifying the Company that, as a result of the Bankruptcy Petitions and in accordance with Nasdaq Listing Rules 5101, 5110(b) and IM-5101-1, the Staff has determined that the Company’s common stock (the “ Securities”) will be delisted from Nasdaq. In addition, on May 6, 2025, the Company received written notice from the Staff notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company’s common stock had closed below the minimum $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “ Minimum Bid Price Requirement”). In the Delisting Notice, the Staff stated that its determination was based on (i) public interest concerns related to the Bankruptcy Petitions, (ii) concerns regarding the residual equity interest of the existing holders of listed Securities and (iii) concerns about the Company’s ability to sustain compliance with all requirements for continued listing on Nasdaq. Specifically, the Staff noted that the Company was not in compliance with the Minimum Bid Price Requirement, nor in compliance with Nasdaq’s Market Value of Listed Securities (as defined under Nasdaq rules) requirement pursuant to Nasdaq Listing Rule 5550(b)(2) (the “ MVLS Requirement”), as previously disclosed in the Company’s Current Report on Form 8-K, filed with the U.S. Securities and Exchange Commission (the “ SEC”) on January 30, 2025. As a result, the Staff determined that the Company’s Minimum Bid Price Requirement and MVLS Requirement deficiencies served as an additional and separate basis for delisting. The Delisting Notice also indicates that the Company may appeal Nasdaq’s determination pursuant to procedures set in the Nasdaq Listing Rule 5800 Series. The Company does not intend to appeal the determination and, therefore, it is expected that the Securities will be delisted. Trading of the Securities will be suspended at the opening of business on May 15, 2025 and a Form 25-NSE will be filed by Nasdaq with the SEC, which will remove the Securities from listing and registration on Nasdaq. The Company expects the Securities will begin trading on the over-the-counter (the “ OTC”) market under the symbol “AXDXQ” on May 15, 2025, but no assurance can be made that trading in the Securities on the OTC market will commence or be maintained.お知らせ • May 09+ 1 more updateMotion for Joint Administration Approved for Accelerate Diagnostics, Inc.The US Bankruptcy Court granted an order for the joint administration of the Chapter 11 bankruptcy cases of Accelerate Diagnostics, Inc. and its affiliates on May 8, 2025. The affiliates include Accelerate Diagnostics Texas, LLC. The cases would be jointly administered for administrative and procedural purposes. Accelerate Diagnostics, Inc. has been designated as the lead debtor.お知らせ • May 08+ 1 more updateMotion for Joint Administration Filed by Accelerate Diagnostics, Inc.Accelerate Diagnostics, Inc., along with its affiliate, filed a motion for joint administration of their Chapter 11 bankruptcy cases in the US Bankruptcy Court on May 8, 2025. As per the motion, the debtor seeks the joint administration of the cases of its affiliate, Accelerate Diagnostics Texas, LLC, with its own case for administrative and procedural purposes. Accelerate Diagnostics, Inc. has been proposed as the lead debtor.お知らせ • Apr 16Accelerate Diagnostics, Inc. Announces Director Appointments, Effective from April 10, 2025On April 10, 2025, the Board of Directors of Accelerate Diagnostics, Inc, unanimously elected Paul Shalhoub and Gilbert Nathan to serve as new directors, effective immediately. Messrs. Shalhoub and Nathan will serve as members of the Board until their successors are elected and qualified or until their earlier death, resignation, disqualification or removal. Mr. Nathan was proposed for election to the Board by certain holders pursuant to their director nomination rights under that certain note purchase agreement, dated August 8, 2024, relating to the Company’s 16.00% Super-Priority Senior Secured PIK Notes due 2025. The Board reviewed Mr. Nathan’s qualifications and unanimously agreed to his appointment. There are no transactions between the Company and either Messrs. Shalhoub or Nathan that would require disclosure under Item 404(a) of Regulation S-K. The Board has determined that Messrs. Shalhoub and Nathan are independent directors under the applicable rules of the Nasdaq Stock Market LLC.お知らせ • Mar 22Accelerate Diagnostics Submits WAVE System and Gram-Negative Positive Blood Culture Menu to the FDA for 510(k) ClearanceAccelerate Diagnostics, Inc. announced the submission of its Accelerate WAVE system and positive blood culture gram-negative test kit to the U.S. Food and Drug Administration (FDA) for 510(k) clearance. The Accelerate WAVE system is designed to provide rapid antimicrobial susceptibility testing (AST) directly from positive blood culture bottles and bacterial isolate colonies. The WAVE system is designed to deliver accurate results in an average of 4.5 hours, enabling same shift targeted antimicrobial therapy for patients with serious infections. With a user-friendly workflow, high throughput capacity, and scalable design, once approved by the FDA, the WAVE system will offer microbiology laboratories a comprehensive AST solution to meet a wide range of testing demands and hospital formulary needs. According to the World Health Organization, sepsis affects an estimated 49 million people globally each year, resulting in approximately 11 million deaths. Of those, around 1.32 million deaths are attributed to bacterial antimicrobial resistance. Sepsis also represents the most significant cost burden to the U.S. healthcare system, with an estimated annual expense of $62 billion. By delivering rapid AST results, the WAVE system is designed to support earlier, targeted antimicrobial therapy-- improving patient outcomes, reducing hospital costs, and helping combat antimicrobial resistance.お知らせ • Jan 30Accelerate Diagnostics Receives Non-Compliance Letter Regarding Nasdaq MVLS RequirementOn January 28, 2025, Accelerate Diagnostics, Inc. (the Company") received written notice (the Notice") from the Listing Qualifications Staff (the Staff") of the Nasdaq Stock Market, LLC (Nasdaq") notifying the Company that, for the last 30 consecutive business days prior to the date of the Notice, the Company's Market Value of Listed Securities (as defined under Nasdaq rules) was below the minimum of $35 million required for continued listing on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(b)(2) (the MVLS Requirement"). In accordance with Nasdaq Listing Rule 5810(c)(3)(C), Nasdaq has provided the Company with 180 calendar days, or until July 28, 2025 (the Compliance Date"), to regain compliance with the MVLS Requirement. If, at any time before the Compliance Date, the Market Value of the Company's common stock (calculated in accordance with Nasdaq rules) closes at $35 million or more for a minimum of ten consecutive business days, Nasdaq will provide written confirmation to the Company and close the matter. The Notice does not result in the delisting of the Company's common stock from the Nasdaq Capital Market. However, in the event the Company does not regain compliance with the MVLS Requirement prior to the Compliance Date, the Company will receive written notification that its common stock will be subject to delisting. At that time, the Company may appeal the Staff's delisting determination to a Nasdaq Hearing Panel. The Company is evaluating potential actions to regain compliance with the MVLS Requirement and intends to actively monitor the market value of its common stock. There can be no assurance that the Company will regain compliance with the MVLS Requirement or otherwise maintain compliance with any of the other Nasdaq listing requirements.お知らせ • Oct 01Accelerate Diagnostics, Inc. Announces FDA Clearance of its Accelerate Arc™? SystemAccelerate Diagnostics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance of the Accelerate Arc system and BC kit, an innovative, automated positive blood culture sample preparation platform, for use with Bruker's MALDI Biotyper®? CA System (MBT-CA System) and MBT-CA Sepsityper®? software extension. Designed for clinical laboratories, the Accelerate Arc system has a simple workflow that automates positive blood culture sample preparation for direct downstream microbial identification (ID) using Bruker's MBT-CA system. This eliminates the need for overnight culture methods, reducing the wait time for microbial ID results, which is critical in the fight against sepsis. The Accelerate Arc system is designed to leverage the breadth of the Bruker MBT-CA reference library to provide rapid ID. This, in conjunction with its future rapid phenotypic antibiotic susceptibility testing (AST) innovation, the Accelerate WAVE™ system1, can enable same shift reporting to Antimicrobial Stewardship teams and clinicians alike. By providing clinicians with rapid ID and AST results, clinicians can get the patient on the optimal antibiotic therapy many hours sooner, which has been shown to improve patient outcomes with Sepsis, reduce antimicrobial resistance rates and hospital costs. The Accelerate Arc system is also designed to supplant both overnight subculture as well as laborious Laboratory Developed Test (LDT) sample preparation methods. Clinical laboratories are under pressure to run FDA-cleared devices due to increased legislation and enforcement associated with the use of LDTs. Accordingly, such laboratories can now utilize the Accelerate Arc system as an automated, FDA-cleared system.お知らせ • Aug 09Accelerate Diagnostics, Inc. Announces Successful Completion of Its Wave Pre-Clinical TrialAccelerate Diagnostics, Inc. announced the successful completion of its WAVE pre-clinical trial. The Accelerate WAVE system is designed to deliver rapid antimicrobial susceptibility testing ("AST") directly from positive blood culture ("PBC") bottles and bacterial isolated colonies ("Isolates") to report accurate results within 4.5 hours, on average. By delivering rapid AST results, patients with serious infections can be put on targeted antimicrobial therapy to improve patient outcomes, cut hospital costs, and reduce antimicrobial resistance. The pre-clinical trial included 1,570 WAVE results compared to Broth Microdilution ("BMD"), the reference method. The trial included an equal number of prospective patient samples and site selected challenge samples which resulted in excellent concordance between sample types. About the Accelerate WAVE System: The Accelerate WAVE system are intended to deliver same-shift antibiotic susceptibility test results enabling antimicrobial stewardship teams and clinicians alike to tailor therapy for patients with serious infections in a timely manner. Getting the patient on optimal therapy, as shown with numerous peer-reviewed publications, not only reduces morbidity associated with bacteremia but also reduces healthcare costs. The WAVE system will offer a comprehensive test menu and incorporates essential features to optimize workflow across laboratories. With full random access for continuous sample loading, the scalability of the Wave system addresses the needs of various health care settings from small community hospitals to large academic centers and reference labs. The WAVE System employs novel holographic imaging technology to determine bacterial growth and morphology changes in real time, enabling same-shift, quantitative usceptibility test results.お知らせ • May 03Accelerate Diagnostics, Inc. to Report Q1, 2024 Results on May 08, 2024Accelerate Diagnostics, Inc. announced that they will report Q1, 2024 results on May 08, 2024お知らせ • May 01Accelerate Diagnostics, Inc. Receives Written Notice from the Listing Qualifications Staff of NasdaqOn April 26, 2024, Accelerate Diagnostics, Inc. (the Company") received written notice from the Listing Qualifications Staff (the Staff") of The Nasdaq Stock Market LLC (Nasdaq") notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company's common stock had closed below the minimum $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the Minimum Bid Price Requirement"). In accordance with Nasdaq rules, the Company has been provided an initial period of 180 calendar days, or until October 23, 2024 (the Compliance Date"), to regain compliance with the Minimum Bid Price Requirement. If, at any time before the Compliance Date, the closing bid price for the Company's common stock is at least $1.00 for a minimum of ten consecutive business days, the Staff will provide the Company written confirmation of compliance with the Minimum Bid Price Requirement and close the matter. If the Company does not regain compliance with the Minimum Bid Price Requirement by the Compliance Date, the Company may be eligible for an additional 180 calendar day compliance period, provided that it meets the continued listing requirement for the market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the Minimum Bid Price Requirement, and notifies the Staff in writing of its intention to cure the deficiency during the additional compliance period. If the Company does not regain compliance with the Minimum Bid Price Requirement by the Compliance Date and is not eligible for an additional compliance period at that time, the Staff will provide written notification to the Company that its common stock will be subject to delisting. At that time, the Company may appeal the Staff's delisting determination to a Nasdaq Hearing Panel. There can be no assurance that the Company will regain compliance with the Minimum Bid Price Requirement or otherwise maintain compliance with any of the other Nasdaq listing requirements. The Company intends to monitor the closing bid price of its common stock and will consider various options available to it if its common stock does not trade at a level to regain compliance with the Minimum Bid Price Requirement. These options include effecting a reverse stock split designed to increase the bid price of the Company's common stock in an amount sufficient to regain compliance with the Minimum Bid Price Requirement. There can be no assurances that a reverse stock split will be consummated or that it will achieve its intended effects.お知らせ • Apr 13Accelerate Diagnostics, Inc., Annual General Meeting, May 07, 2024Accelerate Diagnostics, Inc., Annual General Meeting, May 07, 2024, at 10:30 Pacific Daylight. Agenda: To elect the following 9 persons to serve as directors of the Company (“Directors”) until the 2025 Annual Meeting of Shareholders or until their successors have been duly elected and qualified: Mark Black, Wayne C. Burris, Louise L. Francesconi, Hany Massarany, Marran H. Ogilvie, John Patience, Jack Phillips, Jennifer Regan, and Jack W. Schuler; to ratify the selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for the year ending December 31, 2024; to approve an amendment to the Accelerate Diagnostics, Inc. 2022 Omnibus Equity Incentive Plan (the “2022 Incentive Plan”) to increase the total number of authorized shares of the Company’s common stock (“Shares”) available for grant thereunder by 4,000,000 Shares; and to transact such other business as may properly come before the meeting or any continuation, postponement or adjournment thereof.お知らせ • Mar 06Accelerate Diagnostics, Inc. Receives Written Notice from the Listing Qualifications Staff of the Nasdaq Stock Market, LLCOn March 4, 2024, Accelerate Diagnostics, Inc. (the Company") received written notice (the Notice") from the Listing Qualifications Staff (the Staff") of the Nasdaq Stock Market, LLC (Nasdaq") notifying the Company that for the last 31 consecutive business days prior to the date of the Notice, the Company's Market Value of Listed Securities (as defined under Nasdaq rules) was below the minimum of $35 million required for continued listing on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(b)(2) (the MVLS Requirement"). In accordance with Nasdaq Listing Rule 5810(c)(3)(C), Nasdaq has provided the Company with 180 calendar days, or until September 3, 2024 (the Compliance Date"), to regain compliance with the MVLS Requirement. If, at any time before the Compliance Date, the market value of the Company's common stock (calculated in accordance with Nasdaq rules) closes at $35 million or more for a minimum of ten consecutive business days, Nasdaq will provide written confirmation to the Company and close the matter. The Notice does not result in the delisting of the Company's common stock from the Nasdaq Capital Market. However, in the event the Company does not regain compliance with the MVLS Requirement prior to the Compliance Date, the Company will receive written notification that its common stock will be subject to delisting. At that time, the Company may appeal the Staff's delisting determination to a Nasdaq Hearing Panel. The Company is evaluating potential actions to regain compliance with the MVLS Requirement and intends to actively monitor the market value of its common stock. The Company may also, if appropriate, consider other options to regain compliance with Nasdaq's continued listing standards, such as by increasing its stockholders' equity to at least $2.5 million. There can be no assurance that the Company will regain compliance with the MVLS Requirement or otherwise maintain compliance with any of the other Nasdaq listing requirements.お知らせ • Jan 25Accelerate Diagnostics, Inc. announced that it expects to receive $4.749996 million in funding from Jack W. Schuler Living TrustAccelerate Diagnostics, Inc. announced that it has entered into a securities purchase agreement to issue 33,332 units at a price of $1.5 per unit for the gross proceeds of $49,998 and 2,716,762 units at a price of $1.73 per unit for the gross proceeds of $4,699,998.26 for the total gross proceeds of $4,749,996 on January 25, 2024. The transaction will include participation from individual investors, Chief Executive Officer and Chief Financial Officer for $49,998 and returning investor, Jack W. Schuler Living Trust for $4,749,996. The transaction became effective as of May 20, 2024.お知らせ • Jan 21Accelerate Diagnostics, Inc. has completed a Composite Units Offering.Accelerate Diagnostics, Inc. has completed a Composite Units Offering. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 6,860,659 Price\Range: $1.5 Security Name: Pre-Funded Units Security Type: Equity/Derivative Unit Securities Offered: 6,860,659 Price\Range: $1.49お知らせ • Jul 11Accelerate Diagnostics Announces 1-For-10 Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement of $1.00 Per Share Required to Maintain Continued Listing on the Nasdaq Capital MarketAccelerate Diagnostics, Inc. (the "Company") announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-10. The reverse stock split will become effective at 5:00 p.m. Eastern Time, on July 11, 2023. The Company's common stock will begin trading on a post-split basis at the market open on July 12, 2023, under the Company's existing trading symbol "AXDX". The reverse stock split is part of the Company's plan to regain compliance with the Minimum Bid Price Requirement of $1.00 per share required to maintain continued listing on The Nasdaq Capital Market, among other benefits. The reverse stock split was approved by the Company's stockholders at the Company's Annual Meeting of Stockholders held on May 19, 2023 to be effected in the Board's discretion within approved parameters. The final ratio was approved by the Company's Board on July 7, 2023. The reverse stock split reduces the number of shares of the Company's outstanding common stock from approximately 144 million shares to approximately 14 million shares, subject to adjustment due to the payment of cash in lieu of fractional shares. As a result of the Reverse Stock Split, proportionate adjustments will be made to the number of shares of the Company's common stock underlying the Company's outstanding equity awards, warrants and convertible notes and the number of shares issuable under the Company's equity incentive plans and other existing agreements, as well as the exercise or conversion price, as applicable. There will be no change to the number of authorized shares or the par value per share.Reported Earnings • May 12First quarter 2023 earnings: EPS and revenues miss analyst expectationsFirst quarter 2023 results: US$0.17 loss per share. Revenue: US$2.81m (down 4.9% from 1Q 2022). Net loss: US$16.8m (loss widened 18% from 1Q 2022). Revenue missed analyst estimates by 16%. Earnings per share (EPS) also missed analyst estimates by 17%. Revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 8.3% growth forecast for the Medical Equipment industry in the US.Major Estimate Revision • Apr 25Consensus EPS estimates fall by 15%The consensus outlook for fiscal year 2023 has been updated. 2023 expected loss increased from -US$0.46 to -US$0.53 per share. Revenue forecast of US$15.1m unchanged since last update. Medical Equipment industry in the US expected to see average net income growth of 16% next year. Consensus price target of US$0.60 unchanged from last update. Share price rose 32% to US$0.90 over the past week.分析記事 • Apr 17Market Participants Recognise Accelerate Diagnostics, Inc.'s (NASDAQ:AXDX) Revenues Pushing Shares 38% HigherAccelerate Diagnostics, Inc. ( NASDAQ:AXDX ) shareholders are no doubt pleased to see that the share price has bounced...Reported Earnings • Apr 06Full year 2022 earnings: Revenues and EPS in line with analyst expectationsFull year 2022 results: US$0.76 loss per share (improved from US$1.26 loss in FY 2021). Revenue: US$12.8m (up 8.2% from FY 2021). Net loss: US$62.5m (loss narrowed 20% from FY 2021). Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 7.4% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 57% per year, which means it is significantly lagging earnings.Recent Insider Transactions Derivative • Mar 14CEO, President & Director exercised options and sold US$73k worth of stockOn the 8th of March, Jack Phillips exercised options to acquire 156k shares at no cost and sold these for an average price of US$0.47 per share. This trade did not impact their existing holding. For the year to December 2019, Jack's total compensation was 21% salary and 79% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since March 2022, Jack's direct individual holding has increased from 123.39k shares to 269.46k. Company insiders have collectively sold US$208k more than they bought, via options and on-market transactions in the last 12 months.Reported Earnings • Mar 06Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behindThird quarter 2022 results: US$0.18 loss per share (further deteriorated from US$0.15 loss in 3Q 2021). Revenue: US$2.96m (down 5.2% from 3Q 2021). Net loss: US$15.9m (loss widened 77% from 3Q 2021). Revenue missed analyst estimates by 21%. Earnings per share (EPS) exceeded analyst estimates by 7.7%. Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 7.5% growth forecast for the Medical Equipment industry in the US.Board Change • Mar 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 5 highly experienced directors. CEO, President & Director Jack Phillips was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.お知らせ • Jan 12Accelerate Diagnostics Receives A Deficiency Letter from Nasdaq Regarding Minimum Bid Price RequirementOn January 5, 2023, Accelerate Diagnostics, Inc. ("the Company") received a deficiency letter from the Listing Qualifications Department (the Staff") of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company's common stock had closed below the minimum $1.00 per share requirement for continued inclusion on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the Minimum Bid Price Requirement"). In accordance with Nasdaq rules, the Company has been provided an initial period of 180 calendar days, or until July 5, 2023 (the Compliance Date"), to regain compliance with the Minimum Bid Price Requirement. If, at any time before the Compliance Date, the closing bid price for the Company's common stock is at least $1.00 for a minimum of ten consecutive business days, the Staff will provide the Company written confirmation of compliance with the Minimum Bid Price Requirement. If the Company does not regain compliance with the Minimum Bid Price Requirement by the Compliance Date, the Company may be eligible for an additional 180 calendar day compliance period, provided that it meets the continued listing requirement for the market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the Minimum Bid Price Requirement, and notifies the Staff of its intention to cure the deficiency during the additional compliance period. If the Company does not regain compliance with the Minimum Bid Price Requirement by the Compliance Date and is not eligible for an additional compliance period at that time, the Staff will provide written notification to the Company that its common stock will be subject to delisting. At that time, the Company may appeal the Staff's delisting determination to a Nasdaq Hearing Panel. There can be no assurance that the Company will regain compliance with the Minimum Bid Price Requirement or otherwise maintain compliance with any of the other Nasdaq listing requirements. The Company intends to monitor the closing bid price of its common stock and will consider various options available to it if its common stock does not trade at a level to regain compliance with the Minimum Bid Price Requirement. These options include effecting a reverse stock split designed to increase the bid price of the Company's common stock in an amount sufficient to regain compliance with the Minimum Bid Price Requirement. There can be no assurances that a reverse stock split will be consummated or that it will achieve its intended effects.Major Estimate Revision • Nov 21Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast fell from US$14.4m to US$12.7m. EPS estimate increased from -US$0.81 to -US$0.76 per share. Medical Equipment industry in the US expected to see average net income growth of 14% next year. Consensus price target down from US$4.00 to US$2.00. Share price fell 39% to US$0.92 over the past week.Price Target Changed • Nov 16Price target decreased to US$2.00Down from US$4.00, the current price target is provided by 1 analyst. New target price is 79% above last closing price of US$1.12. Stock is down 80% over the past year. The company is forecast to post a net loss per share of US$0.80 next year compared to a net loss per share of US$1.26 last year.Recent Insider Transactions • Aug 31Insider recently bought US$80k worth of stockOn the 30th of August, Larry Mertz bought around 50k shares on-market at roughly US$1.60 per share. This transaction amounted to 13% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$11m more in shares than they have sold in the last 12 months.Seeking Alpha • Aug 30Accelerate Diagnostics spikes as Chief Technology Officer raises stakeThe shares of in vitro diagnostics firm Accelerate Diagnostics, Inc. (NASDAQ:AXDX) jumped Tuesday after its Chief Technology Officer Larry Michael Mertz announced the purchase of 50K company shares. According to a regulatory filing today, Mr. Mertz bought $80K worth of AXDX shares at $1.60 apiece on Aug. 30, raising his stake by ~13%. The latest transaction comes a week after Mr. Mertz added ~51.7K AXDX shares, increasing his ownership in the company by ~16%. Mertz has served as the Senior Vice President, Head of R&D at AXDX since May 2021. The insider trading comes after the company recently announced a public offering of 17.5M shares of common stock at $2.00 per share. The share issuance was expected to raise $35M in gross proceeds for general corporate purposes and commercialization efforts.Major Estimate Revision • Aug 22Consensus revenue estimates increase by 10%The consensus outlook for revenues in 2022 has improved. 2022 revenue forecast increased from US$12.9m to US$14.3m. Forecast losses expected to reduce from -US$1.04 to -US$0.77 per share. Medical Equipment industry in the US expected to see average net income growth of 9.7% next year. Consensus price target up from US$1.00 to US$4.00. Share price fell 47% to US$1.43 over the past week.分析記事 • Aug 20Need To Know: Analysts Are Much More Bullish On Accelerate Diagnostics, Inc. (NASDAQ:AXDX)Accelerate Diagnostics, Inc. ( NASDAQ:AXDX ) shareholders will have a reason to smile today, with the analysts making...Reported Earnings • Aug 16Second quarter 2022 earnings: EPS and revenues exceed analyst expectationsSecond quarter 2022 results: US$0.23 loss per share (up from US$0.35 loss in 2Q 2021). Revenue: US$3.86m (up 38% from 2Q 2021). Net loss: US$17.8m (loss narrowed 18% from 2Q 2021). Revenue exceeded analyst estimates by 25%. Earnings per share (EPS) also surpassed analyst estimates by 18%. Over the next year, revenue is forecast to grow 11%, compared to a 7.0% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 44% per year, which means it is significantly lagging earnings.Seeking Alpha • Aug 15Accelerate Diagnostics jumps 14% after beating Q2 estimatesVitro diagnostics company dedicated to providing solutions for the global challenges of antibiotic resistance and sepsis, Accelerate Diagnostics (NASDAQ:AXDX) reported Q2 sales of $3.9M, a 39% jump from last year; beats consensus by $0.76M. Growth was driven by increases in both capital and recurring revenues Gross margin was 28% vs. 38%; decline in gross margins resulted from inflation to manufacturing costs and other factors. SG&A costs were $11.5M, vs. $12.9M from prior year. R&D costs were $7.6M, vs. $5.7M. Signed an agreement in August 2022 to exchange $50M of convertible debt due March 2023 for a term loan due in five years with no cash interest due during the term. "In addition to a solid quarter, I am pleased to announce that we will be joining forces with Becton Dickinson to commercialize our products globally. Our global commercial partnership with BD comes at a time when the hospital selling environment is improving, we are firing on all cylinders in R&D and are taking meaningful steps to improve our balance sheet. These are exciting times for our company." commented Jack Phillips, CEO. Total cash, investments, and cash equivalents of $36.8M. GAAP EPS of -$0.23 beats consensus by $0.05. Quant rating of Hold 3.00 with lowest factor grades to profitability. Sell-side analyst give the stock a Hold rating with 3.00 score and an average price target of $1.00 Previously (Aug. 15): Accelerate Diagnostics GAAP EPS of -$0.23 beats by $0.05, revenue of $3.86M beats by $0.76MRecent Insider Transactions Derivative • Jun 27CEO, President & Director exercised options and sold US$26k worth of stockOn the 22nd of June, Jack Phillips exercised options to acquire 28k shares at no cost and sold these for an average price of US$0.91 per share. This trade did not impact their existing holding. For the year to December 2019, Jack's total compensation was 21% salary and 79% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since September 2021, Jack's direct individual holding has increased from 117.04k shares to 208.07k. Company insiders have collectively bought US$10m more than they sold, via options and on-market transactions, in the last 12 months.Major Estimate Revision • May 23Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast fell from US$13.4m to US$12.9m. 2022 losses expected to reduce from -US$1.24 to -US$1.04 per share. Medical Equipment industry in the US expected to see average net income growth of 16% next year. Consensus price target down from US$5.00 to US$1.00. Share price fell 4.8% to US$0.58 over the past week.Reported Earnings • May 17First quarter 2022 earnings: EPS exceeds analyst expectationsFirst quarter 2022 results: US$0.21 loss per share (up from US$0.41 loss in 1Q 2021). Revenue: US$2.96m (up 18% from 1Q 2021). Net loss: US$14.2m (loss narrowed 42% from 1Q 2021). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 30%. Over the next year, revenue is forecast to grow 19%, compared to a 7.9% growth forecast for the industry in the US.Recent Insider Transactions Derivative • Apr 29CEO, President & Director exercised options and sold US$82k worth of stockOn the 28th of April, Jack Phillips exercised options to acquire 84k shares at no cost and sold these for an average price of US$0.98 per share. This trade did not impact their existing holding. For the year to December 2019, Jack's total compensation was 21% salary and 79% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since June 2021, Jack's direct individual holding has increased from 112.70k shares to 123.39k. Company insiders have collectively bought US$10m more than they sold, via options and on-market transactions, in the last 12 months.Price Target Changed • Apr 27Price target decreased to US$5.00Down from US$8.00, the current price target is an average from 4 analysts. New target price is 385% above last closing price of US$1.03. Stock is down 87% over the past year. The company is forecast to post a net loss per share of US$1.23 next year compared to a net loss per share of US$1.26 last year.分析記事 • Mar 15Need To Know: The Consensus Just Cut Its Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Estimates For 2022Market forces rained on the parade of Accelerate Diagnostics, Inc. ( NASDAQ:AXDX ) shareholders today, when the...Major Estimate Revision • Mar 15Consensus revenue estimates fall by 14%The consensus outlook for revenues in 2022 has deteriorated. 2022 revenue forecast decreased from US$15.8m to US$13.6m. Forecast losses increased from -US$1.13 to -US$1.24 per share. Medical Equipment industry in the US expected to see average net income growth of 19% next year. Consensus price target down from US$8.00 to US$5.00. Share price fell 32% to US$1.67 over the past week.Reported Earnings • Mar 09Full year 2021 earnings: EPS exceeds analyst expectationsFull year 2021 results: US$1.26 loss per share (up from US$1.40 loss in FY 2020). Revenue: US$11.8m (up 5.5% from FY 2020). Net loss: US$77.7m (flat on FY 2020). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 13%. Over the next year, revenue is forecast to grow 34%, compared to a 11% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 53% per year, which means it is significantly lagging earnings.Recent Insider Transactions • Feb 03Insider recently bought US$66k worth of stockOn the 31st of January, Hany Massarany bought around 20k shares on-market at roughly US$3.30 per share. In the last 3 months, there was an even bigger purchase from another insider worth US$5.0m. Insiders have collectively bought US$11m more in shares than they have sold in the last 12 months.Recent Insider Transactions • Jan 21Independent Director recently bought US$524k worth of stockOn the 14th of January, Jack Schuler bought around 131k shares on-market at roughly US$4.00 per share. In the last 3 months, they made an even bigger purchase worth US$5.0m. Insiders have collectively bought US$10m more in shares than they have sold in the last 12 months.Recent Insider Transactions • Jan 16Independent Director recently bought US$196k worth of stockOn the 10th of January, Jack Schuler bought around 45k shares on-market at roughly US$4.34 per share. In the last 3 months, they made an even bigger purchase worth US$5.0m. Insiders have collectively bought US$9.8m more in shares than they have sold in the last 12 months.Recent Insider Transactions • Jan 07Independent Director recently bought US$277k worth of stockOn the 29th of December, Jack Schuler bought around 57k shares on-market at roughly US$4.85 per share. In the last 3 months, they made an even bigger purchase worth US$5.0m. Insiders have collectively bought US$9.6m more in shares than they have sold in the last 12 months.Seeking Alpha • Jan 04Accelerate Diagnostics And T2 Biosystems: Financial Woes Set To Continue In 2022Both Accelerate Diagnostics and T2 Biosystems have developed promising technology related to the rapid detection of bacterial infections, notably sepsis. Sepsis is responsible for 270,000 deaths in the U.S. annually, making it hospitals' most deadly killer. It is a $62 billion-per-annum burden on the U.S. health system. Both T2 and Accelerate had a rough 2021, however, with their share prices respectively falling by more than 60% and 30%. Neither company appears able to persuade hospitals that their technologies offer an optimal solution to the problem to rapid detection and treatment of sepsis. That is a major problem for both and the reason I think both stocks could continue to suffer in 2022. T2 already faces delisting; Accelerate's shares have further to fall.Recent Insider Transactions • Dec 24Independent Director recently bought US$369k worth of stockOn the 17th of December, Jack Schuler bought around 74k shares on-market at roughly US$4.98 per share. In the last 3 months, they made an even bigger purchase worth US$5.0m. Insiders have collectively bought US$9.3m more in shares than they have sold in the last 12 months.Recent Insider Transactions • Nov 30Independent Director recently bought US$248k worth of stockOn the 22nd of November, Jack Schuler bought around 49k shares on-market at roughly US$5.06 per share. In the last 3 months, they made an even bigger purchase worth US$1.0m. Insiders have collectively bought US$3.5m more in shares than they have sold in the last 12 months.Recent Insider Transactions • Nov 26Independent Director recently bought US$606k worth of stockOn the 18th of November, Jack Schuler bought around 116k shares on-market at roughly US$5.20 per share. In the last 3 months, they made an even bigger purchase worth US$1.0m. Insiders have collectively bought US$3.3m more in shares than they have sold in the last 12 months.Reported Earnings • Nov 10Third quarter 2021 earnings released: US$0.15 loss per share (vs US$0.33 loss in 3Q 2020)The company reported a decent third quarter result with reduced losses and improved control over expenses, although revenues were weaker. Third quarter 2021 results: Revenue: US$3.12m (down 13% from 3Q 2020). Net loss: US$8.99m (loss narrowed 52% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings.Reported Earnings • Nov 10Third quarter 2021 earnings released: US$0.15 loss per share (vs US$0.33 loss in 3Q 2020)The company reported a decent third quarter result with reduced losses and improved control over expenses, although revenues were weaker. Third quarter 2021 results: Revenue: US$3.12m (down 13% from 3Q 2020). Net loss: US$8.99m (loss narrowed 52% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings.Recent Insider Transactions • Sep 28Independent Director recently bought US$150k worth of stockOn the 23rd of September, Jack Schuler bought around 27k shares on-market at roughly US$5.50 per share. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.Price Target Changed • Sep 24Price target decreased to US$11.00Down from US$12.00, the current price target is an average from 4 analysts. New target price is 102% above last closing price of US$5.44. Stock is down 53% over the past year.Seeking Alpha • Sep 07Accelerate Diagnostics: An Investment AssessmentToday, we take a deeper look at a medical diagnostics firm called Accelerate Diagnostics. Recently, the company launched its AST-focused test kit, successfully concluded its multi-hospital registry study, and continued to advance its commercialization efforts. A full investment analysis is laid out in the paragraphs below.Reported Earnings • Aug 12Second quarter 2021 earnings released: US$0.35 loss per share (vs US$0.35 loss in 2Q 2020)The company reported a solid second quarter result with improved revenues and control over costs, although losses increased. Second quarter 2021 results: Revenue: US$2.80m (up 32% from 2Q 2020). Net loss: US$21.7m (loss widened 13% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 33% per year, which means it is significantly lagging earnings.Major Estimate Revision • Aug 07Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 revenue forecast fell from US$14.7m to US$13.2m. EPS estimate increased from -US$1.36 to -US$1.32 per share. Medical Equipment industry in the US expected to see average net income growth of 20% next year. Consensus price target of US$11.00 unchanged from last update. Share price fell 5.5% to US$7.05 over the past week.Recent Insider Transactions Derivative • Jun 25CEO, President & Director exercised options and sold US$186k worth of stockOn the 22nd of June, Jack Phillips exercised options to acquire 23k shares at no cost and sold these for an average price of US$7.94 per share. This trade did not impact their existing holding. For the year to December 2020, Jack's total compensation was 14% salary and 86% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since March 2021, Jack's direct individual holding has increased from 70.43k shares to 74.02k. Company insiders have collectively sold US$1.5m more than they bought, via options and on-market transactions in the last 12 months.Recent Insider Transactions Derivative • May 16Key Executive exercised options and sold US$56k worth of stockOn the 13th of May, Steve Reichling exercised options to acquire 8k shares at no cost and sold these for an average price of US$6.76 per share. This trade did not impact their existing holding. Since December 2020, Steve has owned 15.58k shares directly. Company insiders have collectively bought US$4.9m more than they sold, via options and on-market transactions, in the last 12 months.Price Target Changed • May 11Price target decreased to US$11.00Down from US$12.33, the current price target is an average from 5 analysts. New target price is 53% above last closing price of US$7.19. Stock is down 28% over the past year.Reported Earnings • May 09First quarter 2021 earnings released: US$0.41 loss per share (vs US$0.39 loss in 1Q 2020)The company reported a soft first quarter result with increased losses and weaker control over costs, although revenues improved. First quarter 2021 results: Revenue: US$2.52m (up 7.5% from 1Q 2020). Net loss: US$24.2m (loss widened 14% from 1Q 2020). Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.Major Estimate Revision • Mar 02Analysts lower revenue estimates to US$16.5mThe 2021 consensus revenue estimate decreased from US$22.5m. Earnings per share (EPS) also decreased, with analysts lowering their estimates from -US$1.24 to -US$1.30 for the same period. The Medical Equipment industry in the US is expected to see an average net income growth of 27% next year. The consensus price target of US$12.33 was unchanged from the last update. Share price is down by 12% to US$10.16 over the past week.Analyst Estimate Surprise Post Earnings • Feb 25Earnings beat expectations, revenue disappointsRevenue missed analyst estimates by 0.3%. Earnings per share (EPS) exceeded analyst estimates by 1.0%. Over the next year, revenue is forecast to grow 47%, compared to a 20% growth forecast for the Medical Equipment industry in the US.Reported Earnings • Feb 25Full year 2020 earnings released: US$1.40 loss per share (vs US$1.55 loss in FY 2019)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: US$11.2m (up 20% from FY 2019). Net loss: US$78.2m (loss narrowed 7.2% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has fallen by 26% per year, which means it is performing significantly worse than earnings.分析記事 • Feb 20Should You Take Comfort From Insider Transactions At Accelerate Diagnostics, Inc. (NASDAQ:AXDX)?We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On...Recent Insider Transactions Derivative • Jan 29Key Executive exercised options and sold US$701k worth of stockOn the 27th of January, Steve Reichling exercised 71k options at a strike price of around US$2.98 and sold these shares for an average price of US$12.90 per share. This trade did not impact their existing holding. Since March 2020, Steve has owned 13.30k shares directly. Company insiders have collectively bought US$17m more than they sold, via options and on-market transactions, in the last 12 months.Is New 90 Day High Low • Jan 26New 90-day high: US$12.96The company is up 30% from its price of US$9.95 on 27 October 2020. The American market is up 17% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 9.0% over the same period.Price Target Changed • Jan 16Price target lowered to US$12.33Down from US$14.33, the current price target is an average from 5 analysts. The new target price is 34% above the current share price of US$9.23. As of last close, the stock is down 47% over the past year.分析記事 • Dec 29Reflecting on Accelerate Diagnostics' (NASDAQ:AXDX) Share Price Returns Over The Last Three YearsIt's not possible to invest over long periods without making some bad investments. But really big losses can really...Is New 90 Day High Low • Dec 10New 90-day low: US$7.04The company is down 33% from its price of US$10.44 on 10 September 2020. The American market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 7.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.Price Target Changed • Dec 06Price target lowered to US$14.33Down from US$16.00, the current price target is an average from 5 analysts. The new target price is 90% above the current share price of US$7.53. As of last close, the stock is down 53% over the past year.Recent Insider Transactions Derivative • Nov 13Key Executive exercised options and sold US$256k worth of stockOn the 9th of November, Steve Reichling exercised 39.33k options at a strike price of around US$2.98 and sold these shares for an average price of US$9.50 per share. This trade did not impact their existing holding. Since March 2020, Steve has owned 13.30k shares directly. Company insiders have collectively bought US$18m more than they sold, via options and on-market transactions, in the last 12 months.Is New 90 Day High Low • Nov 10New 90-day low: US$8.87The company is down 40% from its price of US$14.68 on 12 August 2020. The American market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.Analyst Estimate Surprise Post Earnings • Nov 08Revenue beats expectationsRevenue exceeded analyst estimates by 9.9%. Earnings per share (EPS) were mostly in line with analyst estimates. Over the next year, revenue is forecast to grow 79%, compared to a 16% growth forecast for the Medical Equipment industry in the US.Reported Earnings • Nov 08Third quarter 2020 earnings released: US$0.33 loss per shareThe company reported a solid third quarter result with reduced losses and improved revenues and control over expenses. Third quarter 2020 results: Revenue: US$3.59m (up 58% from 3Q 2019). Net loss: US$18.8m (loss narrowed 8.2% from 3Q 2019). Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has fallen by 20% per year, which means it is performing significantly worse than earnings.Is New 90 Day High Low • Oct 22New 90-day low: US$9.88The company is down 37% from its price of US$15.60 on 24 July 2020. The American market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.お知らせ • Sep 17Accelerate Diagnostics, Inc. Announces New FDA Clearance for Accelerate PhenoTest® ImprovementsAccelerate Diagnostics, Inc. announced that the company has received U.S. Food and Drug Administration (FDA) clearance for a new suite of product enhancements to the Accelerate Pheno® system, which improve performance and expand the system's antimicrobial susceptibility testing (AST) menu for bloodstream infections. The new product release, formally classified as FDA 510(k) Clearance No. K192665, features improvements in susceptibility testing performance for four important antibiotics used to treat Pseudomonas aeruginosa, as well as the addition of the combination of P. aeruginosa and aztreonam, an empiric antibiotic, to the Accelerate PhenoTest BC kit testing panel. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Accelerate Diagnostics は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測OTCPK:AXDX.Q - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/202412-50-25-24N/A9/30/202412-53-27-27N/A6/30/202412-38-33-32N/A3/31/202412-59-37-35N/A12/31/202312-62-41-40N/A9/30/202312-63-43-42N/A6/30/202312-80-48-47N/A3/31/202313-66-50-49N/A12/31/202213-62-49-49N/A9/30/202213-71-52-51N/A6/30/202213-64-51-50N/A3/31/202212-67-48-47N/A12/31/202112-78-48-47N/A9/30/202112-74-46-46N/A6/30/202112-84-47-46N/A3/31/202111-81-47-46N/A12/31/202011-78-52-50N/A9/30/202012-81-55-54N/A6/30/202010-82-60-59N/A3/31/202010-84-64-63N/A12/31/20199-84-65-65N/A9/30/20198-85-66-65N/A6/30/20197-87-66-66N/A3/31/20197-89-71-71N/A12/31/20186-88-69-68N/A9/30/20186-82N/A-67N/A6/30/20185-77N/A-63N/A3/31/20184-71N/A-56N/A12/31/20174-64N/A-56N/A9/30/20172-64N/A-55N/A6/30/20171-64N/A-53N/A3/31/20171-65N/A-56N/A12/31/20160-66N/A-53N/A9/30/20160-63N/A-50N/A6/30/20160-57N/A-47N/A3/31/20160-52N/A-41N/A12/31/20150-45N/A-35N/A9/30/20150-41N/A-30N/A6/30/20150-39N/A-27N/A3/31/20150-35N/A-22N/A12/31/20140-31N/A-19N/A9/30/20140-27N/A-17N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: AXDX.Qの予測収益成長が 貯蓄率 ( 3.1% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: AXDX.Qの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: AXDX.Qの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: AXDX.Qの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: AXDX.Qの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: AXDX.Qの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YHealthcare 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2025/08/22 03:45終値2025/08/20 00:00収益2024/12/31年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Accelerate Diagnostics, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。4 アナリスト機関Sean LavinBTIGAlexander NowakCraig-Hallum Capital Group LLCTycho PetersonJ.P. Morgan1 その他のアナリストを表示
Major Estimate Revision • Apr 25Consensus EPS estimates fall by 15%The consensus outlook for fiscal year 2023 has been updated. 2023 expected loss increased from -US$0.46 to -US$0.53 per share. Revenue forecast of US$15.1m unchanged since last update. Medical Equipment industry in the US expected to see average net income growth of 16% next year. Consensus price target of US$0.60 unchanged from last update. Share price rose 32% to US$0.90 over the past week.
Major Estimate Revision • Nov 21Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast fell from US$14.4m to US$12.7m. EPS estimate increased from -US$0.81 to -US$0.76 per share. Medical Equipment industry in the US expected to see average net income growth of 14% next year. Consensus price target down from US$4.00 to US$2.00. Share price fell 39% to US$0.92 over the past week.
Price Target Changed • Nov 16Price target decreased to US$2.00Down from US$4.00, the current price target is provided by 1 analyst. New target price is 79% above last closing price of US$1.12. Stock is down 80% over the past year. The company is forecast to post a net loss per share of US$0.80 next year compared to a net loss per share of US$1.26 last year.
Major Estimate Revision • Aug 22Consensus revenue estimates increase by 10%The consensus outlook for revenues in 2022 has improved. 2022 revenue forecast increased from US$12.9m to US$14.3m. Forecast losses expected to reduce from -US$1.04 to -US$0.77 per share. Medical Equipment industry in the US expected to see average net income growth of 9.7% next year. Consensus price target up from US$1.00 to US$4.00. Share price fell 47% to US$1.43 over the past week.
Major Estimate Revision • May 23Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast fell from US$13.4m to US$12.9m. 2022 losses expected to reduce from -US$1.24 to -US$1.04 per share. Medical Equipment industry in the US expected to see average net income growth of 16% next year. Consensus price target down from US$5.00 to US$1.00. Share price fell 4.8% to US$0.58 over the past week.
Price Target Changed • Apr 27Price target decreased to US$5.00Down from US$8.00, the current price target is an average from 4 analysts. New target price is 385% above last closing price of US$1.03. Stock is down 87% over the past year. The company is forecast to post a net loss per share of US$1.23 next year compared to a net loss per share of US$1.26 last year.
お知らせ • Aug 19Accelerate Diagnostics, Inc. announced delayed 10-Q filingOn 08/18/2025, Accelerate Diagnostics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Jun 06+ 1 more updateFinal DIP Financing Approved for Accelerate Diagnostics, Inc.The US Bankruptcy Court gave an order to Accelerate Diagnostics, Inc. to obtain DIP financing on final basis on June 5, 2025. As per the order, the debtor has been authorized to obtain a new money term loan facility in the amount of $12.5 million from Indaba Capital Fund, LP and Streeterville Capital LLC with U.S. Bank Trust Company, National Association as DIP agent. As per the terms of the DIP agreement, the loan carries a structuring fee of $1 million, exit fee of $7.5 million and earned in stages 35% at interim order, 15% at dip credit agreement and 50% at final dip order, backstop fee of $1.5 million. The DIP facility would mature either on December 31, 2025, or earliest of loan acceleration or closing of an asset sale, whichever is earlier. Adequate protection would be provided to the DIP lenders in the form of super-priority administrative expense claims which is subject to a carve-out of $0.5 million towards unpaid professional fees / administrative expenses and first priority lien upon and security interest in the debtor’s collateral.
お知らせ • May 17Accelerate Diagnostics, Inc. announced delayed 10-Q filingOn 05/16/2025, Accelerate Diagnostics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • May 16Accelerate Diagnostics, Inc.(OTCPK:AXDX.Q) dropped from NASDAQ Composite IndexAccelerate Diagnostics, Inc has been dropped from the NASDAQ Composite Index
お知らせ • May 13Accelerate Diagnostics Receives Delisting Determination and Minimum Bid Price Non-Compliance Letter from NasdaqAs previously disclosed, on May 8, 2025, Accelerate Diagnostics, Inc. (the “ Company”) and certain of its subsidiaries (together, the “ Debtors”) filed voluntary petitions (the “ Bankruptcy Petitions”) under Chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware (such court, the “ Court” and such cases, the “ Cases”). On May 8, 2025, the Company received written notice (the “ Delisting Notice”) from the Listing Qualifications Staff (the “ Staff”) of The Nasdaq Stock Market LLC (“ Nasdaq”) notifying the Company that, as a result of the Bankruptcy Petitions and in accordance with Nasdaq Listing Rules 5101, 5110(b) and IM-5101-1, the Staff has determined that the Company’s common stock (the “ Securities”) will be delisted from Nasdaq. In addition, on May 6, 2025, the Company received written notice from the Staff notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company’s common stock had closed below the minimum $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “ Minimum Bid Price Requirement”). In the Delisting Notice, the Staff stated that its determination was based on (i) public interest concerns related to the Bankruptcy Petitions, (ii) concerns regarding the residual equity interest of the existing holders of listed Securities and (iii) concerns about the Company’s ability to sustain compliance with all requirements for continued listing on Nasdaq. Specifically, the Staff noted that the Company was not in compliance with the Minimum Bid Price Requirement, nor in compliance with Nasdaq’s Market Value of Listed Securities (as defined under Nasdaq rules) requirement pursuant to Nasdaq Listing Rule 5550(b)(2) (the “ MVLS Requirement”), as previously disclosed in the Company’s Current Report on Form 8-K, filed with the U.S. Securities and Exchange Commission (the “ SEC”) on January 30, 2025. As a result, the Staff determined that the Company’s Minimum Bid Price Requirement and MVLS Requirement deficiencies served as an additional and separate basis for delisting. The Delisting Notice also indicates that the Company may appeal Nasdaq’s determination pursuant to procedures set in the Nasdaq Listing Rule 5800 Series. The Company does not intend to appeal the determination and, therefore, it is expected that the Securities will be delisted. Trading of the Securities will be suspended at the opening of business on May 15, 2025 and a Form 25-NSE will be filed by Nasdaq with the SEC, which will remove the Securities from listing and registration on Nasdaq. The Company expects the Securities will begin trading on the over-the-counter (the “ OTC”) market under the symbol “AXDXQ” on May 15, 2025, but no assurance can be made that trading in the Securities on the OTC market will commence or be maintained.
お知らせ • May 09+ 1 more updateMotion for Joint Administration Approved for Accelerate Diagnostics, Inc.The US Bankruptcy Court granted an order for the joint administration of the Chapter 11 bankruptcy cases of Accelerate Diagnostics, Inc. and its affiliates on May 8, 2025. The affiliates include Accelerate Diagnostics Texas, LLC. The cases would be jointly administered for administrative and procedural purposes. Accelerate Diagnostics, Inc. has been designated as the lead debtor.
お知らせ • May 08+ 1 more updateMotion for Joint Administration Filed by Accelerate Diagnostics, Inc.Accelerate Diagnostics, Inc., along with its affiliate, filed a motion for joint administration of their Chapter 11 bankruptcy cases in the US Bankruptcy Court on May 8, 2025. As per the motion, the debtor seeks the joint administration of the cases of its affiliate, Accelerate Diagnostics Texas, LLC, with its own case for administrative and procedural purposes. Accelerate Diagnostics, Inc. has been proposed as the lead debtor.
お知らせ • Apr 16Accelerate Diagnostics, Inc. Announces Director Appointments, Effective from April 10, 2025On April 10, 2025, the Board of Directors of Accelerate Diagnostics, Inc, unanimously elected Paul Shalhoub and Gilbert Nathan to serve as new directors, effective immediately. Messrs. Shalhoub and Nathan will serve as members of the Board until their successors are elected and qualified or until their earlier death, resignation, disqualification or removal. Mr. Nathan was proposed for election to the Board by certain holders pursuant to their director nomination rights under that certain note purchase agreement, dated August 8, 2024, relating to the Company’s 16.00% Super-Priority Senior Secured PIK Notes due 2025. The Board reviewed Mr. Nathan’s qualifications and unanimously agreed to his appointment. There are no transactions between the Company and either Messrs. Shalhoub or Nathan that would require disclosure under Item 404(a) of Regulation S-K. The Board has determined that Messrs. Shalhoub and Nathan are independent directors under the applicable rules of the Nasdaq Stock Market LLC.
お知らせ • Mar 22Accelerate Diagnostics Submits WAVE System and Gram-Negative Positive Blood Culture Menu to the FDA for 510(k) ClearanceAccelerate Diagnostics, Inc. announced the submission of its Accelerate WAVE system and positive blood culture gram-negative test kit to the U.S. Food and Drug Administration (FDA) for 510(k) clearance. The Accelerate WAVE system is designed to provide rapid antimicrobial susceptibility testing (AST) directly from positive blood culture bottles and bacterial isolate colonies. The WAVE system is designed to deliver accurate results in an average of 4.5 hours, enabling same shift targeted antimicrobial therapy for patients with serious infections. With a user-friendly workflow, high throughput capacity, and scalable design, once approved by the FDA, the WAVE system will offer microbiology laboratories a comprehensive AST solution to meet a wide range of testing demands and hospital formulary needs. According to the World Health Organization, sepsis affects an estimated 49 million people globally each year, resulting in approximately 11 million deaths. Of those, around 1.32 million deaths are attributed to bacterial antimicrobial resistance. Sepsis also represents the most significant cost burden to the U.S. healthcare system, with an estimated annual expense of $62 billion. By delivering rapid AST results, the WAVE system is designed to support earlier, targeted antimicrobial therapy-- improving patient outcomes, reducing hospital costs, and helping combat antimicrobial resistance.
お知らせ • Jan 30Accelerate Diagnostics Receives Non-Compliance Letter Regarding Nasdaq MVLS RequirementOn January 28, 2025, Accelerate Diagnostics, Inc. (the Company") received written notice (the Notice") from the Listing Qualifications Staff (the Staff") of the Nasdaq Stock Market, LLC (Nasdaq") notifying the Company that, for the last 30 consecutive business days prior to the date of the Notice, the Company's Market Value of Listed Securities (as defined under Nasdaq rules) was below the minimum of $35 million required for continued listing on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(b)(2) (the MVLS Requirement"). In accordance with Nasdaq Listing Rule 5810(c)(3)(C), Nasdaq has provided the Company with 180 calendar days, or until July 28, 2025 (the Compliance Date"), to regain compliance with the MVLS Requirement. If, at any time before the Compliance Date, the Market Value of the Company's common stock (calculated in accordance with Nasdaq rules) closes at $35 million or more for a minimum of ten consecutive business days, Nasdaq will provide written confirmation to the Company and close the matter. The Notice does not result in the delisting of the Company's common stock from the Nasdaq Capital Market. However, in the event the Company does not regain compliance with the MVLS Requirement prior to the Compliance Date, the Company will receive written notification that its common stock will be subject to delisting. At that time, the Company may appeal the Staff's delisting determination to a Nasdaq Hearing Panel. The Company is evaluating potential actions to regain compliance with the MVLS Requirement and intends to actively monitor the market value of its common stock. There can be no assurance that the Company will regain compliance with the MVLS Requirement or otherwise maintain compliance with any of the other Nasdaq listing requirements.
お知らせ • Oct 01Accelerate Diagnostics, Inc. Announces FDA Clearance of its Accelerate Arc™? SystemAccelerate Diagnostics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance of the Accelerate Arc system and BC kit, an innovative, automated positive blood culture sample preparation platform, for use with Bruker's MALDI Biotyper®? CA System (MBT-CA System) and MBT-CA Sepsityper®? software extension. Designed for clinical laboratories, the Accelerate Arc system has a simple workflow that automates positive blood culture sample preparation for direct downstream microbial identification (ID) using Bruker's MBT-CA system. This eliminates the need for overnight culture methods, reducing the wait time for microbial ID results, which is critical in the fight against sepsis. The Accelerate Arc system is designed to leverage the breadth of the Bruker MBT-CA reference library to provide rapid ID. This, in conjunction with its future rapid phenotypic antibiotic susceptibility testing (AST) innovation, the Accelerate WAVE™ system1, can enable same shift reporting to Antimicrobial Stewardship teams and clinicians alike. By providing clinicians with rapid ID and AST results, clinicians can get the patient on the optimal antibiotic therapy many hours sooner, which has been shown to improve patient outcomes with Sepsis, reduce antimicrobial resistance rates and hospital costs. The Accelerate Arc system is also designed to supplant both overnight subculture as well as laborious Laboratory Developed Test (LDT) sample preparation methods. Clinical laboratories are under pressure to run FDA-cleared devices due to increased legislation and enforcement associated with the use of LDTs. Accordingly, such laboratories can now utilize the Accelerate Arc system as an automated, FDA-cleared system.
お知らせ • Aug 09Accelerate Diagnostics, Inc. Announces Successful Completion of Its Wave Pre-Clinical TrialAccelerate Diagnostics, Inc. announced the successful completion of its WAVE pre-clinical trial. The Accelerate WAVE system is designed to deliver rapid antimicrobial susceptibility testing ("AST") directly from positive blood culture ("PBC") bottles and bacterial isolated colonies ("Isolates") to report accurate results within 4.5 hours, on average. By delivering rapid AST results, patients with serious infections can be put on targeted antimicrobial therapy to improve patient outcomes, cut hospital costs, and reduce antimicrobial resistance. The pre-clinical trial included 1,570 WAVE results compared to Broth Microdilution ("BMD"), the reference method. The trial included an equal number of prospective patient samples and site selected challenge samples which resulted in excellent concordance between sample types. About the Accelerate WAVE System: The Accelerate WAVE system are intended to deliver same-shift antibiotic susceptibility test results enabling antimicrobial stewardship teams and clinicians alike to tailor therapy for patients with serious infections in a timely manner. Getting the patient on optimal therapy, as shown with numerous peer-reviewed publications, not only reduces morbidity associated with bacteremia but also reduces healthcare costs. The WAVE system will offer a comprehensive test menu and incorporates essential features to optimize workflow across laboratories. With full random access for continuous sample loading, the scalability of the Wave system addresses the needs of various health care settings from small community hospitals to large academic centers and reference labs. The WAVE System employs novel holographic imaging technology to determine bacterial growth and morphology changes in real time, enabling same-shift, quantitative usceptibility test results.
お知らせ • May 03Accelerate Diagnostics, Inc. to Report Q1, 2024 Results on May 08, 2024Accelerate Diagnostics, Inc. announced that they will report Q1, 2024 results on May 08, 2024
お知らせ • May 01Accelerate Diagnostics, Inc. Receives Written Notice from the Listing Qualifications Staff of NasdaqOn April 26, 2024, Accelerate Diagnostics, Inc. (the Company") received written notice from the Listing Qualifications Staff (the Staff") of The Nasdaq Stock Market LLC (Nasdaq") notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company's common stock had closed below the minimum $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the Minimum Bid Price Requirement"). In accordance with Nasdaq rules, the Company has been provided an initial period of 180 calendar days, or until October 23, 2024 (the Compliance Date"), to regain compliance with the Minimum Bid Price Requirement. If, at any time before the Compliance Date, the closing bid price for the Company's common stock is at least $1.00 for a minimum of ten consecutive business days, the Staff will provide the Company written confirmation of compliance with the Minimum Bid Price Requirement and close the matter. If the Company does not regain compliance with the Minimum Bid Price Requirement by the Compliance Date, the Company may be eligible for an additional 180 calendar day compliance period, provided that it meets the continued listing requirement for the market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the Minimum Bid Price Requirement, and notifies the Staff in writing of its intention to cure the deficiency during the additional compliance period. If the Company does not regain compliance with the Minimum Bid Price Requirement by the Compliance Date and is not eligible for an additional compliance period at that time, the Staff will provide written notification to the Company that its common stock will be subject to delisting. At that time, the Company may appeal the Staff's delisting determination to a Nasdaq Hearing Panel. There can be no assurance that the Company will regain compliance with the Minimum Bid Price Requirement or otherwise maintain compliance with any of the other Nasdaq listing requirements. The Company intends to monitor the closing bid price of its common stock and will consider various options available to it if its common stock does not trade at a level to regain compliance with the Minimum Bid Price Requirement. These options include effecting a reverse stock split designed to increase the bid price of the Company's common stock in an amount sufficient to regain compliance with the Minimum Bid Price Requirement. There can be no assurances that a reverse stock split will be consummated or that it will achieve its intended effects.
お知らせ • Apr 13Accelerate Diagnostics, Inc., Annual General Meeting, May 07, 2024Accelerate Diagnostics, Inc., Annual General Meeting, May 07, 2024, at 10:30 Pacific Daylight. Agenda: To elect the following 9 persons to serve as directors of the Company (“Directors”) until the 2025 Annual Meeting of Shareholders or until their successors have been duly elected and qualified: Mark Black, Wayne C. Burris, Louise L. Francesconi, Hany Massarany, Marran H. Ogilvie, John Patience, Jack Phillips, Jennifer Regan, and Jack W. Schuler; to ratify the selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for the year ending December 31, 2024; to approve an amendment to the Accelerate Diagnostics, Inc. 2022 Omnibus Equity Incentive Plan (the “2022 Incentive Plan”) to increase the total number of authorized shares of the Company’s common stock (“Shares”) available for grant thereunder by 4,000,000 Shares; and to transact such other business as may properly come before the meeting or any continuation, postponement or adjournment thereof.
お知らせ • Mar 06Accelerate Diagnostics, Inc. Receives Written Notice from the Listing Qualifications Staff of the Nasdaq Stock Market, LLCOn March 4, 2024, Accelerate Diagnostics, Inc. (the Company") received written notice (the Notice") from the Listing Qualifications Staff (the Staff") of the Nasdaq Stock Market, LLC (Nasdaq") notifying the Company that for the last 31 consecutive business days prior to the date of the Notice, the Company's Market Value of Listed Securities (as defined under Nasdaq rules) was below the minimum of $35 million required for continued listing on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(b)(2) (the MVLS Requirement"). In accordance with Nasdaq Listing Rule 5810(c)(3)(C), Nasdaq has provided the Company with 180 calendar days, or until September 3, 2024 (the Compliance Date"), to regain compliance with the MVLS Requirement. If, at any time before the Compliance Date, the market value of the Company's common stock (calculated in accordance with Nasdaq rules) closes at $35 million or more for a minimum of ten consecutive business days, Nasdaq will provide written confirmation to the Company and close the matter. The Notice does not result in the delisting of the Company's common stock from the Nasdaq Capital Market. However, in the event the Company does not regain compliance with the MVLS Requirement prior to the Compliance Date, the Company will receive written notification that its common stock will be subject to delisting. At that time, the Company may appeal the Staff's delisting determination to a Nasdaq Hearing Panel. The Company is evaluating potential actions to regain compliance with the MVLS Requirement and intends to actively monitor the market value of its common stock. The Company may also, if appropriate, consider other options to regain compliance with Nasdaq's continued listing standards, such as by increasing its stockholders' equity to at least $2.5 million. There can be no assurance that the Company will regain compliance with the MVLS Requirement or otherwise maintain compliance with any of the other Nasdaq listing requirements.
お知らせ • Jan 25Accelerate Diagnostics, Inc. announced that it expects to receive $4.749996 million in funding from Jack W. Schuler Living TrustAccelerate Diagnostics, Inc. announced that it has entered into a securities purchase agreement to issue 33,332 units at a price of $1.5 per unit for the gross proceeds of $49,998 and 2,716,762 units at a price of $1.73 per unit for the gross proceeds of $4,699,998.26 for the total gross proceeds of $4,749,996 on January 25, 2024. The transaction will include participation from individual investors, Chief Executive Officer and Chief Financial Officer for $49,998 and returning investor, Jack W. Schuler Living Trust for $4,749,996. The transaction became effective as of May 20, 2024.
お知らせ • Jan 21Accelerate Diagnostics, Inc. has completed a Composite Units Offering.Accelerate Diagnostics, Inc. has completed a Composite Units Offering. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 6,860,659 Price\Range: $1.5 Security Name: Pre-Funded Units Security Type: Equity/Derivative Unit Securities Offered: 6,860,659 Price\Range: $1.49
お知らせ • Jul 11Accelerate Diagnostics Announces 1-For-10 Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement of $1.00 Per Share Required to Maintain Continued Listing on the Nasdaq Capital MarketAccelerate Diagnostics, Inc. (the "Company") announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-10. The reverse stock split will become effective at 5:00 p.m. Eastern Time, on July 11, 2023. The Company's common stock will begin trading on a post-split basis at the market open on July 12, 2023, under the Company's existing trading symbol "AXDX". The reverse stock split is part of the Company's plan to regain compliance with the Minimum Bid Price Requirement of $1.00 per share required to maintain continued listing on The Nasdaq Capital Market, among other benefits. The reverse stock split was approved by the Company's stockholders at the Company's Annual Meeting of Stockholders held on May 19, 2023 to be effected in the Board's discretion within approved parameters. The final ratio was approved by the Company's Board on July 7, 2023. The reverse stock split reduces the number of shares of the Company's outstanding common stock from approximately 144 million shares to approximately 14 million shares, subject to adjustment due to the payment of cash in lieu of fractional shares. As a result of the Reverse Stock Split, proportionate adjustments will be made to the number of shares of the Company's common stock underlying the Company's outstanding equity awards, warrants and convertible notes and the number of shares issuable under the Company's equity incentive plans and other existing agreements, as well as the exercise or conversion price, as applicable. There will be no change to the number of authorized shares or the par value per share.
Reported Earnings • May 12First quarter 2023 earnings: EPS and revenues miss analyst expectationsFirst quarter 2023 results: US$0.17 loss per share. Revenue: US$2.81m (down 4.9% from 1Q 2022). Net loss: US$16.8m (loss widened 18% from 1Q 2022). Revenue missed analyst estimates by 16%. Earnings per share (EPS) also missed analyst estimates by 17%. Revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 8.3% growth forecast for the Medical Equipment industry in the US.
Major Estimate Revision • Apr 25Consensus EPS estimates fall by 15%The consensus outlook for fiscal year 2023 has been updated. 2023 expected loss increased from -US$0.46 to -US$0.53 per share. Revenue forecast of US$15.1m unchanged since last update. Medical Equipment industry in the US expected to see average net income growth of 16% next year. Consensus price target of US$0.60 unchanged from last update. Share price rose 32% to US$0.90 over the past week.
分析記事 • Apr 17Market Participants Recognise Accelerate Diagnostics, Inc.'s (NASDAQ:AXDX) Revenues Pushing Shares 38% HigherAccelerate Diagnostics, Inc. ( NASDAQ:AXDX ) shareholders are no doubt pleased to see that the share price has bounced...
Reported Earnings • Apr 06Full year 2022 earnings: Revenues and EPS in line with analyst expectationsFull year 2022 results: US$0.76 loss per share (improved from US$1.26 loss in FY 2021). Revenue: US$12.8m (up 8.2% from FY 2021). Net loss: US$62.5m (loss narrowed 20% from FY 2021). Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 7.4% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 57% per year, which means it is significantly lagging earnings.
Recent Insider Transactions Derivative • Mar 14CEO, President & Director exercised options and sold US$73k worth of stockOn the 8th of March, Jack Phillips exercised options to acquire 156k shares at no cost and sold these for an average price of US$0.47 per share. This trade did not impact their existing holding. For the year to December 2019, Jack's total compensation was 21% salary and 79% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since March 2022, Jack's direct individual holding has increased from 123.39k shares to 269.46k. Company insiders have collectively sold US$208k more than they bought, via options and on-market transactions in the last 12 months.
Reported Earnings • Mar 06Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behindThird quarter 2022 results: US$0.18 loss per share (further deteriorated from US$0.15 loss in 3Q 2021). Revenue: US$2.96m (down 5.2% from 3Q 2021). Net loss: US$15.9m (loss widened 77% from 3Q 2021). Revenue missed analyst estimates by 21%. Earnings per share (EPS) exceeded analyst estimates by 7.7%. Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 7.5% growth forecast for the Medical Equipment industry in the US.
Board Change • Mar 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 5 highly experienced directors. CEO, President & Director Jack Phillips was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
お知らせ • Jan 12Accelerate Diagnostics Receives A Deficiency Letter from Nasdaq Regarding Minimum Bid Price RequirementOn January 5, 2023, Accelerate Diagnostics, Inc. ("the Company") received a deficiency letter from the Listing Qualifications Department (the Staff") of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company's common stock had closed below the minimum $1.00 per share requirement for continued inclusion on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the Minimum Bid Price Requirement"). In accordance with Nasdaq rules, the Company has been provided an initial period of 180 calendar days, or until July 5, 2023 (the Compliance Date"), to regain compliance with the Minimum Bid Price Requirement. If, at any time before the Compliance Date, the closing bid price for the Company's common stock is at least $1.00 for a minimum of ten consecutive business days, the Staff will provide the Company written confirmation of compliance with the Minimum Bid Price Requirement. If the Company does not regain compliance with the Minimum Bid Price Requirement by the Compliance Date, the Company may be eligible for an additional 180 calendar day compliance period, provided that it meets the continued listing requirement for the market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the Minimum Bid Price Requirement, and notifies the Staff of its intention to cure the deficiency during the additional compliance period. If the Company does not regain compliance with the Minimum Bid Price Requirement by the Compliance Date and is not eligible for an additional compliance period at that time, the Staff will provide written notification to the Company that its common stock will be subject to delisting. At that time, the Company may appeal the Staff's delisting determination to a Nasdaq Hearing Panel. There can be no assurance that the Company will regain compliance with the Minimum Bid Price Requirement or otherwise maintain compliance with any of the other Nasdaq listing requirements. The Company intends to monitor the closing bid price of its common stock and will consider various options available to it if its common stock does not trade at a level to regain compliance with the Minimum Bid Price Requirement. These options include effecting a reverse stock split designed to increase the bid price of the Company's common stock in an amount sufficient to regain compliance with the Minimum Bid Price Requirement. There can be no assurances that a reverse stock split will be consummated or that it will achieve its intended effects.
Major Estimate Revision • Nov 21Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast fell from US$14.4m to US$12.7m. EPS estimate increased from -US$0.81 to -US$0.76 per share. Medical Equipment industry in the US expected to see average net income growth of 14% next year. Consensus price target down from US$4.00 to US$2.00. Share price fell 39% to US$0.92 over the past week.
Price Target Changed • Nov 16Price target decreased to US$2.00Down from US$4.00, the current price target is provided by 1 analyst. New target price is 79% above last closing price of US$1.12. Stock is down 80% over the past year. The company is forecast to post a net loss per share of US$0.80 next year compared to a net loss per share of US$1.26 last year.
Recent Insider Transactions • Aug 31Insider recently bought US$80k worth of stockOn the 30th of August, Larry Mertz bought around 50k shares on-market at roughly US$1.60 per share. This transaction amounted to 13% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$11m more in shares than they have sold in the last 12 months.
Seeking Alpha • Aug 30Accelerate Diagnostics spikes as Chief Technology Officer raises stakeThe shares of in vitro diagnostics firm Accelerate Diagnostics, Inc. (NASDAQ:AXDX) jumped Tuesday after its Chief Technology Officer Larry Michael Mertz announced the purchase of 50K company shares. According to a regulatory filing today, Mr. Mertz bought $80K worth of AXDX shares at $1.60 apiece on Aug. 30, raising his stake by ~13%. The latest transaction comes a week after Mr. Mertz added ~51.7K AXDX shares, increasing his ownership in the company by ~16%. Mertz has served as the Senior Vice President, Head of R&D at AXDX since May 2021. The insider trading comes after the company recently announced a public offering of 17.5M shares of common stock at $2.00 per share. The share issuance was expected to raise $35M in gross proceeds for general corporate purposes and commercialization efforts.
Major Estimate Revision • Aug 22Consensus revenue estimates increase by 10%The consensus outlook for revenues in 2022 has improved. 2022 revenue forecast increased from US$12.9m to US$14.3m. Forecast losses expected to reduce from -US$1.04 to -US$0.77 per share. Medical Equipment industry in the US expected to see average net income growth of 9.7% next year. Consensus price target up from US$1.00 to US$4.00. Share price fell 47% to US$1.43 over the past week.
分析記事 • Aug 20Need To Know: Analysts Are Much More Bullish On Accelerate Diagnostics, Inc. (NASDAQ:AXDX)Accelerate Diagnostics, Inc. ( NASDAQ:AXDX ) shareholders will have a reason to smile today, with the analysts making...
Reported Earnings • Aug 16Second quarter 2022 earnings: EPS and revenues exceed analyst expectationsSecond quarter 2022 results: US$0.23 loss per share (up from US$0.35 loss in 2Q 2021). Revenue: US$3.86m (up 38% from 2Q 2021). Net loss: US$17.8m (loss narrowed 18% from 2Q 2021). Revenue exceeded analyst estimates by 25%. Earnings per share (EPS) also surpassed analyst estimates by 18%. Over the next year, revenue is forecast to grow 11%, compared to a 7.0% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 44% per year, which means it is significantly lagging earnings.
Seeking Alpha • Aug 15Accelerate Diagnostics jumps 14% after beating Q2 estimatesVitro diagnostics company dedicated to providing solutions for the global challenges of antibiotic resistance and sepsis, Accelerate Diagnostics (NASDAQ:AXDX) reported Q2 sales of $3.9M, a 39% jump from last year; beats consensus by $0.76M. Growth was driven by increases in both capital and recurring revenues Gross margin was 28% vs. 38%; decline in gross margins resulted from inflation to manufacturing costs and other factors. SG&A costs were $11.5M, vs. $12.9M from prior year. R&D costs were $7.6M, vs. $5.7M. Signed an agreement in August 2022 to exchange $50M of convertible debt due March 2023 for a term loan due in five years with no cash interest due during the term. "In addition to a solid quarter, I am pleased to announce that we will be joining forces with Becton Dickinson to commercialize our products globally. Our global commercial partnership with BD comes at a time when the hospital selling environment is improving, we are firing on all cylinders in R&D and are taking meaningful steps to improve our balance sheet. These are exciting times for our company." commented Jack Phillips, CEO. Total cash, investments, and cash equivalents of $36.8M. GAAP EPS of -$0.23 beats consensus by $0.05. Quant rating of Hold 3.00 with lowest factor grades to profitability. Sell-side analyst give the stock a Hold rating with 3.00 score and an average price target of $1.00 Previously (Aug. 15): Accelerate Diagnostics GAAP EPS of -$0.23 beats by $0.05, revenue of $3.86M beats by $0.76M
Recent Insider Transactions Derivative • Jun 27CEO, President & Director exercised options and sold US$26k worth of stockOn the 22nd of June, Jack Phillips exercised options to acquire 28k shares at no cost and sold these for an average price of US$0.91 per share. This trade did not impact their existing holding. For the year to December 2019, Jack's total compensation was 21% salary and 79% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since September 2021, Jack's direct individual holding has increased from 117.04k shares to 208.07k. Company insiders have collectively bought US$10m more than they sold, via options and on-market transactions, in the last 12 months.
Major Estimate Revision • May 23Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast fell from US$13.4m to US$12.9m. 2022 losses expected to reduce from -US$1.24 to -US$1.04 per share. Medical Equipment industry in the US expected to see average net income growth of 16% next year. Consensus price target down from US$5.00 to US$1.00. Share price fell 4.8% to US$0.58 over the past week.
Reported Earnings • May 17First quarter 2022 earnings: EPS exceeds analyst expectationsFirst quarter 2022 results: US$0.21 loss per share (up from US$0.41 loss in 1Q 2021). Revenue: US$2.96m (up 18% from 1Q 2021). Net loss: US$14.2m (loss narrowed 42% from 1Q 2021). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 30%. Over the next year, revenue is forecast to grow 19%, compared to a 7.9% growth forecast for the industry in the US.
Recent Insider Transactions Derivative • Apr 29CEO, President & Director exercised options and sold US$82k worth of stockOn the 28th of April, Jack Phillips exercised options to acquire 84k shares at no cost and sold these for an average price of US$0.98 per share. This trade did not impact their existing holding. For the year to December 2019, Jack's total compensation was 21% salary and 79% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since June 2021, Jack's direct individual holding has increased from 112.70k shares to 123.39k. Company insiders have collectively bought US$10m more than they sold, via options and on-market transactions, in the last 12 months.
Price Target Changed • Apr 27Price target decreased to US$5.00Down from US$8.00, the current price target is an average from 4 analysts. New target price is 385% above last closing price of US$1.03. Stock is down 87% over the past year. The company is forecast to post a net loss per share of US$1.23 next year compared to a net loss per share of US$1.26 last year.
分析記事 • Mar 15Need To Know: The Consensus Just Cut Its Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Estimates For 2022Market forces rained on the parade of Accelerate Diagnostics, Inc. ( NASDAQ:AXDX ) shareholders today, when the...
Major Estimate Revision • Mar 15Consensus revenue estimates fall by 14%The consensus outlook for revenues in 2022 has deteriorated. 2022 revenue forecast decreased from US$15.8m to US$13.6m. Forecast losses increased from -US$1.13 to -US$1.24 per share. Medical Equipment industry in the US expected to see average net income growth of 19% next year. Consensus price target down from US$8.00 to US$5.00. Share price fell 32% to US$1.67 over the past week.
Reported Earnings • Mar 09Full year 2021 earnings: EPS exceeds analyst expectationsFull year 2021 results: US$1.26 loss per share (up from US$1.40 loss in FY 2020). Revenue: US$11.8m (up 5.5% from FY 2020). Net loss: US$77.7m (flat on FY 2020). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 13%. Over the next year, revenue is forecast to grow 34%, compared to a 11% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 53% per year, which means it is significantly lagging earnings.
Recent Insider Transactions • Feb 03Insider recently bought US$66k worth of stockOn the 31st of January, Hany Massarany bought around 20k shares on-market at roughly US$3.30 per share. In the last 3 months, there was an even bigger purchase from another insider worth US$5.0m. Insiders have collectively bought US$11m more in shares than they have sold in the last 12 months.
Recent Insider Transactions • Jan 21Independent Director recently bought US$524k worth of stockOn the 14th of January, Jack Schuler bought around 131k shares on-market at roughly US$4.00 per share. In the last 3 months, they made an even bigger purchase worth US$5.0m. Insiders have collectively bought US$10m more in shares than they have sold in the last 12 months.
Recent Insider Transactions • Jan 16Independent Director recently bought US$196k worth of stockOn the 10th of January, Jack Schuler bought around 45k shares on-market at roughly US$4.34 per share. In the last 3 months, they made an even bigger purchase worth US$5.0m. Insiders have collectively bought US$9.8m more in shares than they have sold in the last 12 months.
Recent Insider Transactions • Jan 07Independent Director recently bought US$277k worth of stockOn the 29th of December, Jack Schuler bought around 57k shares on-market at roughly US$4.85 per share. In the last 3 months, they made an even bigger purchase worth US$5.0m. Insiders have collectively bought US$9.6m more in shares than they have sold in the last 12 months.
Seeking Alpha • Jan 04Accelerate Diagnostics And T2 Biosystems: Financial Woes Set To Continue In 2022Both Accelerate Diagnostics and T2 Biosystems have developed promising technology related to the rapid detection of bacterial infections, notably sepsis. Sepsis is responsible for 270,000 deaths in the U.S. annually, making it hospitals' most deadly killer. It is a $62 billion-per-annum burden on the U.S. health system. Both T2 and Accelerate had a rough 2021, however, with their share prices respectively falling by more than 60% and 30%. Neither company appears able to persuade hospitals that their technologies offer an optimal solution to the problem to rapid detection and treatment of sepsis. That is a major problem for both and the reason I think both stocks could continue to suffer in 2022. T2 already faces delisting; Accelerate's shares have further to fall.
Recent Insider Transactions • Dec 24Independent Director recently bought US$369k worth of stockOn the 17th of December, Jack Schuler bought around 74k shares on-market at roughly US$4.98 per share. In the last 3 months, they made an even bigger purchase worth US$5.0m. Insiders have collectively bought US$9.3m more in shares than they have sold in the last 12 months.
Recent Insider Transactions • Nov 30Independent Director recently bought US$248k worth of stockOn the 22nd of November, Jack Schuler bought around 49k shares on-market at roughly US$5.06 per share. In the last 3 months, they made an even bigger purchase worth US$1.0m. Insiders have collectively bought US$3.5m more in shares than they have sold in the last 12 months.
Recent Insider Transactions • Nov 26Independent Director recently bought US$606k worth of stockOn the 18th of November, Jack Schuler bought around 116k shares on-market at roughly US$5.20 per share. In the last 3 months, they made an even bigger purchase worth US$1.0m. Insiders have collectively bought US$3.3m more in shares than they have sold in the last 12 months.
Reported Earnings • Nov 10Third quarter 2021 earnings released: US$0.15 loss per share (vs US$0.33 loss in 3Q 2020)The company reported a decent third quarter result with reduced losses and improved control over expenses, although revenues were weaker. Third quarter 2021 results: Revenue: US$3.12m (down 13% from 3Q 2020). Net loss: US$8.99m (loss narrowed 52% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings.
Reported Earnings • Nov 10Third quarter 2021 earnings released: US$0.15 loss per share (vs US$0.33 loss in 3Q 2020)The company reported a decent third quarter result with reduced losses and improved control over expenses, although revenues were weaker. Third quarter 2021 results: Revenue: US$3.12m (down 13% from 3Q 2020). Net loss: US$8.99m (loss narrowed 52% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings.
Recent Insider Transactions • Sep 28Independent Director recently bought US$150k worth of stockOn the 23rd of September, Jack Schuler bought around 27k shares on-market at roughly US$5.50 per share. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.
Price Target Changed • Sep 24Price target decreased to US$11.00Down from US$12.00, the current price target is an average from 4 analysts. New target price is 102% above last closing price of US$5.44. Stock is down 53% over the past year.
Seeking Alpha • Sep 07Accelerate Diagnostics: An Investment AssessmentToday, we take a deeper look at a medical diagnostics firm called Accelerate Diagnostics. Recently, the company launched its AST-focused test kit, successfully concluded its multi-hospital registry study, and continued to advance its commercialization efforts. A full investment analysis is laid out in the paragraphs below.
Reported Earnings • Aug 12Second quarter 2021 earnings released: US$0.35 loss per share (vs US$0.35 loss in 2Q 2020)The company reported a solid second quarter result with improved revenues and control over costs, although losses increased. Second quarter 2021 results: Revenue: US$2.80m (up 32% from 2Q 2020). Net loss: US$21.7m (loss widened 13% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 33% per year, which means it is significantly lagging earnings.
Major Estimate Revision • Aug 07Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 revenue forecast fell from US$14.7m to US$13.2m. EPS estimate increased from -US$1.36 to -US$1.32 per share. Medical Equipment industry in the US expected to see average net income growth of 20% next year. Consensus price target of US$11.00 unchanged from last update. Share price fell 5.5% to US$7.05 over the past week.
Recent Insider Transactions Derivative • Jun 25CEO, President & Director exercised options and sold US$186k worth of stockOn the 22nd of June, Jack Phillips exercised options to acquire 23k shares at no cost and sold these for an average price of US$7.94 per share. This trade did not impact their existing holding. For the year to December 2020, Jack's total compensation was 14% salary and 86% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since March 2021, Jack's direct individual holding has increased from 70.43k shares to 74.02k. Company insiders have collectively sold US$1.5m more than they bought, via options and on-market transactions in the last 12 months.
Recent Insider Transactions Derivative • May 16Key Executive exercised options and sold US$56k worth of stockOn the 13th of May, Steve Reichling exercised options to acquire 8k shares at no cost and sold these for an average price of US$6.76 per share. This trade did not impact their existing holding. Since December 2020, Steve has owned 15.58k shares directly. Company insiders have collectively bought US$4.9m more than they sold, via options and on-market transactions, in the last 12 months.
Price Target Changed • May 11Price target decreased to US$11.00Down from US$12.33, the current price target is an average from 5 analysts. New target price is 53% above last closing price of US$7.19. Stock is down 28% over the past year.
Reported Earnings • May 09First quarter 2021 earnings released: US$0.41 loss per share (vs US$0.39 loss in 1Q 2020)The company reported a soft first quarter result with increased losses and weaker control over costs, although revenues improved. First quarter 2021 results: Revenue: US$2.52m (up 7.5% from 1Q 2020). Net loss: US$24.2m (loss widened 14% from 1Q 2020). Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.
Major Estimate Revision • Mar 02Analysts lower revenue estimates to US$16.5mThe 2021 consensus revenue estimate decreased from US$22.5m. Earnings per share (EPS) also decreased, with analysts lowering their estimates from -US$1.24 to -US$1.30 for the same period. The Medical Equipment industry in the US is expected to see an average net income growth of 27% next year. The consensus price target of US$12.33 was unchanged from the last update. Share price is down by 12% to US$10.16 over the past week.
Analyst Estimate Surprise Post Earnings • Feb 25Earnings beat expectations, revenue disappointsRevenue missed analyst estimates by 0.3%. Earnings per share (EPS) exceeded analyst estimates by 1.0%. Over the next year, revenue is forecast to grow 47%, compared to a 20% growth forecast for the Medical Equipment industry in the US.
Reported Earnings • Feb 25Full year 2020 earnings released: US$1.40 loss per share (vs US$1.55 loss in FY 2019)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: US$11.2m (up 20% from FY 2019). Net loss: US$78.2m (loss narrowed 7.2% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has fallen by 26% per year, which means it is performing significantly worse than earnings.
分析記事 • Feb 20Should You Take Comfort From Insider Transactions At Accelerate Diagnostics, Inc. (NASDAQ:AXDX)?We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On...
Recent Insider Transactions Derivative • Jan 29Key Executive exercised options and sold US$701k worth of stockOn the 27th of January, Steve Reichling exercised 71k options at a strike price of around US$2.98 and sold these shares for an average price of US$12.90 per share. This trade did not impact their existing holding. Since March 2020, Steve has owned 13.30k shares directly. Company insiders have collectively bought US$17m more than they sold, via options and on-market transactions, in the last 12 months.
Is New 90 Day High Low • Jan 26New 90-day high: US$12.96The company is up 30% from its price of US$9.95 on 27 October 2020. The American market is up 17% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 9.0% over the same period.
Price Target Changed • Jan 16Price target lowered to US$12.33Down from US$14.33, the current price target is an average from 5 analysts. The new target price is 34% above the current share price of US$9.23. As of last close, the stock is down 47% over the past year.
分析記事 • Dec 29Reflecting on Accelerate Diagnostics' (NASDAQ:AXDX) Share Price Returns Over The Last Three YearsIt's not possible to invest over long periods without making some bad investments. But really big losses can really...
Is New 90 Day High Low • Dec 10New 90-day low: US$7.04The company is down 33% from its price of US$10.44 on 10 September 2020. The American market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 7.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.
Price Target Changed • Dec 06Price target lowered to US$14.33Down from US$16.00, the current price target is an average from 5 analysts. The new target price is 90% above the current share price of US$7.53. As of last close, the stock is down 53% over the past year.
Recent Insider Transactions Derivative • Nov 13Key Executive exercised options and sold US$256k worth of stockOn the 9th of November, Steve Reichling exercised 39.33k options at a strike price of around US$2.98 and sold these shares for an average price of US$9.50 per share. This trade did not impact their existing holding. Since March 2020, Steve has owned 13.30k shares directly. Company insiders have collectively bought US$18m more than they sold, via options and on-market transactions, in the last 12 months.
Is New 90 Day High Low • Nov 10New 90-day low: US$8.87The company is down 40% from its price of US$14.68 on 12 August 2020. The American market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.
Analyst Estimate Surprise Post Earnings • Nov 08Revenue beats expectationsRevenue exceeded analyst estimates by 9.9%. Earnings per share (EPS) were mostly in line with analyst estimates. Over the next year, revenue is forecast to grow 79%, compared to a 16% growth forecast for the Medical Equipment industry in the US.
Reported Earnings • Nov 08Third quarter 2020 earnings released: US$0.33 loss per shareThe company reported a solid third quarter result with reduced losses and improved revenues and control over expenses. Third quarter 2020 results: Revenue: US$3.59m (up 58% from 3Q 2019). Net loss: US$18.8m (loss narrowed 8.2% from 3Q 2019). Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has fallen by 20% per year, which means it is performing significantly worse than earnings.
Is New 90 Day High Low • Oct 22New 90-day low: US$9.88The company is down 37% from its price of US$15.60 on 24 July 2020. The American market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.
お知らせ • Sep 17Accelerate Diagnostics, Inc. Announces New FDA Clearance for Accelerate PhenoTest® ImprovementsAccelerate Diagnostics, Inc. announced that the company has received U.S. Food and Drug Administration (FDA) clearance for a new suite of product enhancements to the Accelerate Pheno® system, which improve performance and expand the system's antimicrobial susceptibility testing (AST) menu for bloodstream infections. The new product release, formally classified as FDA 510(k) Clearance No. K192665, features improvements in susceptibility testing performance for four important antibiotics used to treat Pseudomonas aeruginosa, as well as the addition of the combination of P. aeruginosa and aztreonam, an empiric antibiotic, to the Accelerate PhenoTest BC kit testing panel.